Christina Takke
Founder at V-Bio Ventures BV
Network origin in Christina Takke first degree
Entity | Entity type | Industry | |
---|---|---|---|
Precirix NV
Precirix NV Pharmaceuticals: MajorHealth Technology Precirix NV develops and distributes radio-immunotherapeutic drugs for cancer patients. The company was founded on October 14, 2014 by Jens De Vos, Ludwig Camusot, Nick Devoogdt, Geert Raes, Tony Lahoutte and Matthias Dhuyvetter and is headquartered in Brussels, Belgium.
11
| Holding Company | Pharmaceuticals: Major | 11 |
Forbion Capital Partners Management Holding BV
Forbion Capital Partners Management Holding BV Investment ManagersFinance Forbion Capital Partners Management Holding BV (Forbion) is a Netherlands-based venture capital firm which was founded by Bart Bergstein. Headquartered in Naarden, the firm specializes in late-stage and early-stage clinical development programs to optimize the commercial potential of their investee company's technologies.
9
| Private Company | Investment Managers | 9 |
Confo Therapeutics NV
Confo Therapeutics NV Pharmaceuticals: MajorHealth Technology Confo Therapeutics NV develops pharmaceutical products. It is a drug discovery company building internal drug discovery programs on GPCRs addressing unmet medical need. The company was founded by Jan Steyaert and Toon Laeremans in June 2015 and is headquartered in Brussels, Belgium.
8
| Holding Company | Pharmaceuticals: Major | 8 |
V-Bio Ventures BV
V-Bio Ventures BV Investment ManagersFinance V-Bio Ventures BV is an Independent Venture Capital firm founded in 2015 by Christina Takke and Willem Broekaert. V-Bio Ventures BV is headquartered in Ghent.
7
| Private Company | Investment Managers | 7 |
Syndesi Therapeutics SA
Syndesi Therapeutics SA Miscellaneous Commercial ServicesCommercial Services Syndesi Therapeutics SA develops novel therapeutics for cognitive impairment which includes Alzheimer’s disease, dementias, and cognitive impairment associated with schizophrenia. The company is headquartered in Louvain-la-Neuve, Belgium.
7
| Subsidiary | Miscellaneous Commercial Services | 7 |
V-Bio Management 1 BV
V-Bio Management 1 BV Financial ConglomeratesFinance Part of V-Bio Ventures BV, V-Bio Management 1 BV functions as an investment holding Belgian company. The company is based in Ghent, Belgium.
1
| Subsidiary | Financial Conglomerates | 1 |
Chart of Companies connected to the second degree
Multi-company connection
Companies connected to Christina Takke via their personal network
Company | Sector | Related people | Main position |
---|---|---|---|
ABBOTT LABORATORIES | Medical Specialties | Public Communications Contact | |
AMGEN INC. | Pharmaceuticals: Major | Corporate Officer/Principal Corporate Officer/Principal | |
PFIZER, INC. | Pharmaceuticals: Major | Corporate Officer/Principal Corporate Officer/Principal | |
enGene, Inc.
enGene, Inc. BiotechnologyHealth Technology enGene, Inc. develops therapeutic solutions for the treatment of metabolic diseases. It operates as a biotechnology company which develops a mucosal immunotherapy platform for treating several prevalent, chronic diseases including inflammatory bowel disease and diabetes. The firm also develops proprietary, non-integrating biopolymer based nucleotide DNA and siRNA delivery technology that facilitates localized delivery of immune-modulating proteins to the intestinal mucosa for treating various immune disorders. The company was founded in 1999 by Anthony T. Cheung, John C. Brown, Timothy J. Kieffer, and Francis John Gargiulo and is headquartered in Vancouver, Canada. | Biotechnology | Director/Board Member Director/Board Member | |
BioVex, Inc.
BioVex, Inc. Pharmaceuticals: MajorHealth Technology BioVex, Inc. develops vaccines for the treatment of cancer and the prevention of chronic infectious diseases. Its products include OncoVEX oncolytic and ImmunoVEX technology. The company was founded in 1999 by Dr. Robert Coffin and is headquartered in Woburn, MA. | Pharmaceuticals: Major | Chief Executive Officer Director/Board Member | |
BioVex Group, Inc.
BioVex Group, Inc. BiotechnologyHealth Technology BioVex Group, Inc. operates as a clinical-stage biotechnology company. It focuses on the development and commercialization of targeted treatments for cancer and the prevention of infectious disease. The company was founded in 1999 and is headquartered in Woburn, MA. | Biotechnology | Chief Executive Officer Director/Board Member | |
Forbion Co-Investment II Coöperatief UA
Forbion Co-Investment II Coöperatief UA Investment ManagersFinance Part of Forbion Capital Partners Management Holding BV, the venture capital firm, Forbion Co-Investment II Coöperatief UA, is based in Naarden, Netherlands. Forbion Co-Investment II Coöperatief UA operates as a venture capital firm. The Dutch company was founded in 2000 by Bart Bergstein, Hugo Alexander Slootweg, Martien van Osch. | Investment Managers | Founder Founder | |
Fujirebio Europe NV
Fujirebio Europe NV Medical SpecialtiesHealth Technology Fujirebio Europe NV develops and markets diagnostic products to improve therapy management and patient health. It focuses on molecular diagnostics and multiparameter testing. The firm also provides LUMIPULSE G1200, an automated chemiluminescent enzyme immunoassay system; LUMIPULSE G600 II, an automated benchtop CLEIA system, routine and novel markers for the oncology sector. The company was founded in 1985 by Philippe Leboulch and is headquartered in Ghent, Belgium. | Medical Specialties | Public Communications Contact | |
Cortendo AB
Cortendo AB Miscellaneous Commercial ServicesCommercial Services Cortendo AB engages in the provision of biopharmaceutical business. Its activities include development and distribution of orphan drugs for metabolic and endocrine diseases as well as diabetes. Its products include cortisol inhibition and normocort. The company was founded on October 6, 1996 and is headquartered in Trevose, PA. | Miscellaneous Commercial Services | Director/Board Member | |
Sopartec SA
Sopartec SA Investment ManagersFinance Sopartec SA is the investment and technology valorization arm of Université Catholique de Louvain (UCL) and was founded in 1942. Sopartec SA is headquartered in Louvain-la-Neuve, Belgium. | Investment Managers | Private Equity Investor | |
Participatiemaatschappij Vlaanderen NV
Participatiemaatschappij Vlaanderen NV Investment ManagersFinance Participatiemaatschappij Vlaanderen NV (PMV) is a private equity/venture capital firm, a subsidiary of Region of Flanders founded in 1995. Participatiemaatschappij Vlaanderen NV is headquartered in Brussels, Belgium. | Investment Managers | Private Equity Investor Private Equity Investor | |
University of Amsterdam | College/University | Doctorate Degree Undergraduate Degree | |
University of Utrecht | College/University | Doctorate Degree Graduate Degree | |
University of Groningen | College/University | Graduate Degree Graduate Degree | |
Vrije Universiteit Amsterdam | College/University | Undergraduate Degree Graduate Degree | |
Université Libre de Bruxelles | College/University | Graduate Degree Undergraduate Degree | |
Ogeda SA
Ogeda SA Pharmaceuticals: MajorHealth Technology Ogeda SA discovers and develops small molecule drugs. It develops NK3 antagonists for the treatment of hormone-dependent pathologies in the field of Women's Health. The company was founded in 1994 and is headquartered in Gosselies, Spain. | Pharmaceuticals: Major | Chief Executive Officer Director of Finance/CFO | |
Merck Serono SA
Merck Serono SA Medical SpecialtiesHealth Technology Merck Serono SA operates as a holding company in the pharmaceutical field. It engages in the research, development, manufacture, and distribution of therapeutic products for the treatment of human diseases. The company was founded on May 21, 1987 and is headquartered in Coinsins, Switzerland. | Medical Specialties | Director/Board Member | |
Stichting Publieke Private Samenwerking Versterking
Stichting Publieke Private Samenwerking Versterking Investment Trusts/Mutual FundsMiscellaneous Stichting Mibiton promotes research, development, and entrepreneurship in the life sciences sector. The foundation is focused on biomedical sciences, chemistry, food, agricultural, and environmental technology. Stichting Mibiton was founded in 1994, formally called as Stichting Publieke Private Samenwerking Versterking van de Materiële Infrastructuur BioTechnologisch Onderzoek in Nederland and is based in The Hague, The Netherlands. | Investment Trusts/Mutual Funds | Director/Board Member Corporate Officer/Principal | |
reMYND NV
reMYND NV Miscellaneous Commercial ServicesCommercial Services reMYND NV engages in the development of disease-modifying treatments against alzheimer's, parkinson's, diabetes and other protein misfolding disorders. Its drug and development unit focuses on innovative, disease-modifying drugs for treating degenerative disorders. The company was founded by Fred Van Leuven, Stefaan Wera and Joris Winderickx in 2002 and is headquartered in Leuven, Belgium. | Miscellaneous Commercial Services | Director/Board Member | |
AM-Pharma BV
AM-Pharma BV BiotechnologyHealth Technology AM-Pharma BV operates as a biopharmaceutical company. It engages in the development of proprietary recombinant human Alkaline Phosphatase. The firm’s products include Acute Kidney Injury, Inflammatory Bowel Diseases and Hypophosphatasia. The company was founded in 2001 and is headquartered in Bunnik, the Netherlands. | Biotechnology | Director/Board Member Director/Board Member | |
Exosome Diagnostics, Inc.
Exosome Diagnostics, Inc. Medical/Nursing ServicesHealth Services Exosome Diagnostics, Inc. develops and commercializes biofluid-based diagnostics to deliver personalized precision healthcare that improves lives. Its novel exosome-based technology platform can yield comprehensive and dynamic molecular insights to transform how cancer and other serious diseases are detected, diagnosed, treated and monitored. The company was founded by Wayne D. Comper, Harvey J. Barnett and James R. McCullough and is headquartered in Waltham, MA. | Medical/Nursing Services | Director/Board Member Director/Board Member | |
UNIQURE N.V. | Biotechnology | Chairman Founder Director/Board Member | |
Rainier Therapeutics, Inc.
Rainier Therapeutics, Inc. BiotechnologyHealth Technology Rainier Therapeutics, Inc. operates as a biotechnology company that develops a targeted biologic for the potential treatment of metastatic bladder cancer. It provides Vofatamab, an antibody that is focused on the fibroblast growth factor of bladder and other cancer. The company was founded by Stephen Lau and is headquartered in San Leandro, CA. | Biotechnology | Director/Board Member | |
Glionova AB
Glionova AB Pharmaceuticals: MajorHealth Technology Glionova AB develops cancer treatment drugs. The firm is a drug discovery and development company. It offers GLN-1001 product. The company was founded by Lars G. J. Hammarström and Patrik Ernfors in 2014 and is headquartered in Stockholm, Sweden. | Pharmaceuticals: Major | Director/Board Member | |
REPLIMUNE GROUP, INC. | Biotechnology | Founder Director/Board Member Director/Board Member | |
Healthneed AB | Director/Board Member | ||
NMD Pharma A/S
NMD Pharma A/S BiotechnologyHealth Technology NMD Pharma ApS engages with the research and preparation of small molecules targeting an undisclosed ion. It offers medical treatment of neuromuscular diseases for patients with chronic muscle wasting diseases such as myasthenia gravis and amyotrophic lateral sclerosis. The company was founded by Ole B?kgaard Nielsen, Thomas Holm Pedersen, and Claus Elsborg Olesen on May 7, 2015 and is headquartered in Aarhus, Denmark. | Biotechnology | Director/Board Member Director/Board Member | |
ViroVet NV
ViroVet NV Pharmaceuticals: MajorHealth Technology ViroVet NV is a Belgian company that focuses on the discovery, licensing, and development of biopharmaceutical products for livestock. The company is based in Leuven, Belgium. ViroVet was founded by Erwin Blomsma, Stefaan Wera, and Nesya Goris, with Erwin Blomsma serving as the CEO since incorporation. | Pharmaceuticals: Major | Director/Board Member | |
Aphea.Bio SA
Aphea.Bio SA BiotechnologyHealth Technology Aphea.Bio SA engages in research and development of biotechnology and agricultural products. It develops next generation biopesticides and biostimulants based on natural microorganisms. The company was founded by Isabel Vercauteren and Steven Vandenabeele in December 5, 2016 and is headquartered in Ghent, Belgium. | Biotechnology | Director/Board Member | |
Epics Therapeutics SA
Epics Therapeutics SA Miscellaneous Commercial ServicesCommercial Services EPICS Therapeutics SA engages in the development of therapeutic solutions for cancer. The company was founded by Jean Combalbert, Alain Parthoens and Francois Fuks on February 20, 2018 and is headquartered in Charleroi, Belgium. | Miscellaneous Commercial Services | Founder Director/Board Member | |
ADCendo ApS
ADCendo ApS BiotechnologyHealth Technology ADCendo ApS is a Danish company that is focused on developing antibody-drug conjugates (ADCs) to treat underserved cancers. The company is based in Humlebaek, Denmark. The company completed a series A extension financing round in 2023, which brought its funds to 82 million EUR to advance into clinical development. The investors in the company include Novo Holdings, Ysios Capital, Pontifax Venture Capital, RA Capital Management, HealthCap, and Gilde Healthcare. The company was founded in 2017 by Christoffer Nielsen, Henrik Stage. Michael Pehl has been the CEO of the company since 2021. | Biotechnology | Director/Board Member | |
Oxyrane, Ltd. | Chairman Director/Board Member | ||
AgomAb Therapeutics NV
AgomAb Therapeutics NV Miscellaneous Commercial ServicesCommercial Services AgomAb Therapeutics NV operates as a Belgian biotherapeutics company, developing agonistic antibodies for regeneration of damaged tissues. The company was founded by Paolo Michieli, Manuela Cazzanti, Virginia Morello, Federica Caterina Linty, Michael Potter Saunders, and Hans J. W. de Haard in 2017 and is headquartered in Ghent, Belgium. | Miscellaneous Commercial Services | Director/Board Member Director/Board Member | |
Pulsify Medical BV
Pulsify Medical BV Medical SpecialtiesHealth Technology Pulsify Medical BV is a Belgian digital medical technology company that specializes in developing wearable ultrasound patches. The company is based in Louvain, Belgium. Pulsify Medical was founded in 2019 by Lieven Herbots, Xavier Rottenberg, Jan D'hooge, Steve Stoffels. Iwan van Vijfeijken has been the CEO of the company since 2019. | Medical Specialties | Director/Board Member | |
Priothera Ltd.
Priothera Ltd. BiotechnologyHealth Technology Priothera Ltd. engages in the development of orally delivered sphingosine-1-phosphate (S1P) receptor modulators for hematological malignancies. The company was founded by Florent Gros, Shaval Patel, and Brice Suire in 2020 and is headquartered in Dublin, Ireland. | Biotechnology | Director/Board Member | |
Hemab ApS
Hemab ApS BiotechnologyHealth Technology Hemab ApS develops antibodies for the treatment of rare bleeding disorders. The company is based in Copenhagen, Denmark. The Danish company was founded in 2019 by Johan Henrik Faber. Benny Sorensen has been the CEO of the company since 2020. | Biotechnology | Director/Board Member | |
VectorY BV
VectorY BV Miscellaneous Commercial ServicesCommercial Services VectorY BV is a biotech company based in Amsterdam, Netherlands, that is dedicated to developing transformative medicines for people with neurodegenerative diseases such as ALS, Huntington's, and Parkinson's. VectorY's platform combines the promise of precise therapeutic antibodies with one-time AAV-based delivery to the CNS, enabling long-lasting CNS treatment after a single administration using cutting-edge antibody, AAV, and manufacturing technologies. The Dutch company's unique in-house expertise in antibodies, AAV vectors, protein degradation, manufacturing, and neuroscience drives the rapid development of much-needed disease-modifying therapies for neurodegenerative diseases. The company was founded by Sander J. van Deventer and Pavlina Konstantinova, with Sander J. van Deventer serving as the CEO since incorporation. | Miscellaneous Commercial Services | Chief Executive Officer Director/Board Member Director/Board Member | |
Dualyx NV
Dualyx NV Miscellaneous Commercial ServicesCommercial Services Dualyx NV is a biotech company based in Ghent, Belgium that focuses on developing novel Treg-based therapies for patients with difficult-to-treat autoimmune diseases. The CEO of the company is Wouter Verhoeven, and it is located in Zwijnaarde, Belgium. Dualyx has developed a pipeline of highly promising immune modulating programs, including DT-001, an antibody agonist program targeting the TNF receptor 2 (TNFR2), which is currently in IND-enabling studies. The Belgian company aims to create next-generation biologic drugs for autoimmunity therapies with novel mechanisms of action, lower toxicity, and improved patient outcomes than traditional therapeutics. The company was founded in 2020 by Luc van Rompaey in collaboration with Wurzburg University, Argenx, VIB, Ghent University, and KU Leuven. | Miscellaneous Commercial Services | Director/Board Member Director/Board Member | |
Mahzi Therapeutics, Inc.
Mahzi Therapeutics, Inc. BiotechnologyHealth Technology Mahzi Therapeutics is a private biotechnology company that focuses on genetic therapies for rare genetic neurodevelopmental disorders. The company was founded by Yael Weiss and is based in San Mateo, CA. The company unites patient and family groups, academic researchers, diagnostic companies, other industry members, and its internal team of experts to develop therapies for patients with these serious diseases. Mahzi's team is experienced in all aspects of biopharmaceutical research, development, and manufacturing and is driven to make a difference in the lives of patients with rare genetic diseases. Yael Weiss has been the CEO since incorporation. | Biotechnology | Director/Board Member | |
NewAmsterdam Pharma BV
NewAmsterdam Pharma BV Pharmaceuticals: MajorHealth Technology NewAmsterdam Pharma BV develops novel drugs to treat dyslipidemia. It operates as a biotechnology company and develops anti-dyslipidemic compounds in cardiovascular disease indications. The firm's product DEZ-001 develops a potent cholesteryl ester transfer protein inhibitor that has shown a decrease of low-density lipoprotein levels, and an increase of high-density lipoprotein levels. The company was founded by John J. P. Kastelein in 2012 and is headquartered in Naarden, the Netherlands. | Pharmaceuticals: Major | Founder Chairman Director/Board Member |
Statistics
International
United States | 14 |
Belgium | 14 |
Netherlands | 12 |
United Kingdom | 4 |
Sweden | 4 |
Sectoral
Health Technology | 28 |
Commercial Services | 9 |
Finance | 6 |
Consumer Services | 6 |
Distribution Services | 2 |
Operational
Director/Board Member | 232 |
Corporate Officer/Principal | 44 |
Private Equity Investor | 31 |
Chairman | 27 |
Founder | 24 |
Most connected contacts
Insiders | |
---|---|
Hugo Slootweg | 34 |
Dieter Weinand | 32 |
Fiona MacLaughlin | 22 |
Marten Steen | 21 |
Edward van Wezel | 20 |
Ruth Devenyns | 18 |
Geert-Jan Mulder | 17 |
Sander J. van Deventer | 17 |
Karl Nägler | 16 |
Alexandra Tolia | 15 |
Marco Boorsma | 15 |
Robert Scott | 15 |
Avraham Molcho | 13 |
Bart Bergstein | 12 |
Martinus Adrianus van Osch | 12 |
- Stock Market
- Insiders
- Christina Takke
- Company connections